Aurinia Pharmaceuticals Inc

NASDAQ: AUPH
$8.20
-$0.10 (-1.1%)
Real Time Data Delayed 15 Min.

AUPH Stock Chart and Intraday Price

AUPH Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address #140, 14315 - 118 AVENUE, EDMONTON, AB, CANADA
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 835.89M USD
Shares Outstanding 144,618,000
Aurinia Pharmaceuticals Inc is a biopharmaceutical company based in Edmonton, Canada, dedicated to the development and commercialization of treatments for diseases lacking sufficient medical solutions. Its flagship product, LUPKYNIS, is designed for adults with active lupus nephritis, showcasing the company's focus on addressing significant unmet medical needs. Aurinia Pharmaceuticals also collaborates with Otsuka Pharmaceutical Co., Ltd., highlighting its commitment to expanding its impact and reach in healthcare.

AUPH Articles

Insiders Are Loading Up on These 4 Biotech Stocks Now
Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the past week.
Trey Thoelcke
Published:

Insiders Are Loving These 6 Stocks Right Now
The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as a specialty retailer.
Trey Thoelcke
Published:
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.